Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Patent
1995-05-11
1998-04-07
Achutamurthy, Ponnathapura
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
435236, A61K 3912, C12N 704
Patent
active
057361487
ABSTRACT:
cDNA clones containing the entire genome of Japanese encephalitis virus (JEV) were used to produce infectious, recombinant JEV particles with diverse virulence properties. Certain viruses retained the immunogenicity of JEV, but lacked the ability to cause encephalitis. The mutation associated with this loss of neurovirulence was localized to a nucleotide substitution in the codon encoding the 138th amino acid of the envelop protein, resulting in a mutation of an acidic amino acid to a basic amino acid. Attenuated viruses containing this mutation form the basis of a greatly improved, molecularly defined vaccine for the prevention of Japanese encephalitis in humans.
REFERENCES:
Kaluzova et al. "Reverted Virulence of attenuated tick-borne encephalitis rus mutant is not accompanied with the changes in deduced viral envelope protein amino acid sequence" Acta Virologica 38: 133-140, 1994.
Aihara et al., "Identification of Mutations That Occurred on the Genome of Japanese Encephalitis Virus During the Attenuation Process" Virus Genes 5: 95-109 (1991).
Bowie et al., "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions" Science 237: 1306-1310 (Mar. 16, 1990).
Davis et al., "Attenuating Mutations in the E2 Glycoprotein Gene of Venezuelan Equine Encephalitis Virus: Construction of Single and Multiple Mutants in a Full-Length cDNA Clone" Virology 183:20-31 (1991).
Eckels et al., "Japanese encephalitis virus live-attenuated vaccine, Chinese strain SA.sub.14 -14-2; adaptation to primary canine kidney cell cultures and preparation of a vaccine for human use" Vaccine 6: 513-518 (1988).
Kumar et al., "Amino acid variations at a single residue in an autoimmune peptide profoundly affect its.
Mason et al., "Japanese Encephalitis Virus-Vaccinia Recombinants Produce Particulte Forms of the Structural Membrane Proteins and Induce High Levels of Protection Against Lethal . . . " Virology 180: 294-305 (1991).
Nitayaphan et al., "Nucleotide Sequence of the Virulent SA-14 Strain of Japanese Encephalitis Virus and Its Attenuated Vaccine Derivative, SA-14-14-2" Virology 177: 541-552 (1990).
Schlesinger et al., "New Approaches to Flavivirus Vaccine Development" Biotechnology 20:280-307 (1992).
Sumiyoshi et al., "Infectious Japanese Encephalitis Virus RNA Can Be Synthesized from In Vitro-Ligated cDNA Templates" J. Virol. 66: 5425-5431 (Sep. 1992).
Sumiyoshi et al., "Characterization of a Highly Attenuated Japanese Encephalitis Virus Generated from Molecularly Cloned cDNA" J. Infect. Dis. 171: 1144-1151 (May 1995).
Vaughn et al., "The Epidemiology of Japanese Encephalitis: Prospects for Prevention" Epidem. Rev. 14:197-221 (1992).
Venugopal et al., "Towards a new generation of flavivirus vaccines" Vaccine 12:966-975 (1994).
Hoke, Jr. Charles H.
Sumiyoshi Hideo
Achutamurthy Ponnathapura
Bui Phuong T.
The United States of America as represented by the Secretary of
LandOfFree
Infectious Japanese encephalitis virus cDNA clones that produce does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Infectious Japanese encephalitis virus cDNA clones that produce , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Infectious Japanese encephalitis virus cDNA clones that produce will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-10426